Loss of Annexin A10 Expression Is Associated with Poor Prognosis in Early Gastric Cancer

Abstract

Gastric cancer (GC) is the third most common cause of cancer-related mortality. The diagnosis and treatment of early GC is a crucial strategy for prognostic improvement of GC. Annexin A10 (ANXA10), a calcium-/phospholipid-binding protein, is a member of the annexin family. The significance of ANXA10 expression in early GC remains unclear. This is the first report to investigate ANXA10 expression in early GC. We performed immunohistochemistry to evaluate ANXA10 expression in early GC, and the correlation between ANXA10 and clinicopathological factors. The loss of ANXA10 expression was detected in 63 (61.2%) of 103 early GC cases and significantly correlated with poor overall survival in patients. Sex, pT stage, pN stage, histology, and ANXA10 expression were associated with poor survival. Sex, histology, and ANXA10 expression were determined as independent predictors of survival in early GC patients. ANXA10 immunostaining could be a new decision-making biomarker in GC.

Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma

“…However, the most interesting observation was the significance of ANXA10 expression in SBA. Previous reports have shown that ANXA10 is an independent prognostic factor in several carcinomas: hepatocellular carcinoma (12), cholangiocarcinoma (24), ovarian cancer (25), thyroid cancer (26), and early gastric cancers (15). These results suggest that ANXA10 immunostaining is a clinically significant modality to predict survival of SBA patients.…”

“…In SBA tissue, ANXA10 expression was detected in the nuclei and cytoplasm of tumour cells (Figure 2E and F). We defined immunostaining as positive if 10% of the SBA cancer cell nuclei showed visible signals, according to previous studies (14,15). A total of 17 (56.7%) SBA samples showed ANXA10 expression.…”

“…Immunohistochemistry. IHC staining was performed based on previously described methods with some modifications (14,15). For IHC evaluation, paraffin-embedded tissue samples from 30 representative blocks were cut into 4 μm-thick sections, deparaffinized, and rehydrated.…”

“…Several carcinomas have been reported to express ANXA10, including carcinomas of the liver (12), gastrointestine (11), and oesophagus (13). We have previously reported that ANXA10 is associated with the gastric phenotype of gastric cancer through the regulation of pancreatic duodenal homeobox-1 (PDX1) (14) and that ANXA10 is associated with early-stage gastric cancer (15). Previous studies have suggested that some SBA cases have been known to express gastric mucin (MUC5AC and MUC6) and have the gastric phenotype (16).…”

Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma

“…The expression of short isoform mRNA of annexin A10, previously mistaken as annexin A10, was associated with favorable prognosis in hepatocellular carcinoma [ 11 ]. Expression of annexin A10 was associated with good prognosis of diffuse-type gastric carcinoma [ 12 , 13 ], but poor prognosis in intestinal-type gastric carcinoma, papillary thyroid cancer, small bowel adenocarcinoma, and serous epithelial ovarian cancer [ 13 – 16 ]. A recent study reported that annexin A10 expression was associated with poor prognosis for the perihilar and distal cholangiocarcinoma but not for the intrahepatic cholangiocarcinoma.…”